Comparing the Effect of Combining Exercise with Rosuvastatin versus Atorvastatin on Lipid Profile and Functional Capacity: A Retrospective Cohort Study

الملخص EN

Background.

Statins and exercise are recommended for managing hypercholesterolemia.

However, statin types may vary in their interaction with exercise.

We compared rosuvastatin versus atorvastatin combination with exercise on lipid profile and functional capacity.

Methods.

A retrospective cohort study using data from a 12-week cardiovascular rehabilitation program between 2014 and 2016.

Statin use was determined through prescriptions, and the average exercise minutes/week were computed from exercise logs.

The outcomes were changes in total cholesterol, low- and high-density lipoproteins (LDL and HDL), triglycerides, and functional capacity (6-minute walk test (6MWT)).

Directed acyclic graphs were used to identify potential confounders, accounted for using multiple linear regression modeling.

Results.

The cohort included 282 patients from 106 atorvastatin and 176 rosuvastatin users.

The average exercise minutes/week was 109.4±66.1 among atorvastatin and 106.7±49.1 among rosuvastatin users.

Interaction models suggested that a higher number of exercise minutes/week were more favorable among atorvastatin users on total cholesterol and LDL (0.004, 95% CI: 0.001, 0.008 and 0.004, 95% CI: 0.001, 0.007, respectively) but did not reach significance for HDL and triglycerides.

Rosuvastatin use was associated with greater increases in 6MWT; however, we observed no between-group differences in interaction estimates by the type of statin used.

Conclusion.

Rosuvastatin use could blunt the beneficial effect of exercise on LDL and total cholesterol compared to atorvastatin.

No significant differences were observed in triglycerides, HDL, and functional capacity levels.

Additional studies are warranted with randomized treatments and larger samples.

Healthcare providers should continue prescribing statins alongside recommending exercise modalities, with a careful follow-up for rosuvastatin users.